Global Hepatocellular Carcinoma Treatment Market 2023
The global hepatocellular carcinoma (HCC) treatment market is projected to reach USD 8.05 billion by 2029, growing at a CAGR of 13.4% from 2023 to 2029. HCC is the most common type of liver cancer, accounting for 89% of cases. It has a low survival rate of less than 5% and is influenced by factors like hepatitis, aflatoxin exposure, and liver cirrhosis. The HCC treatment pipeline includes over 155 assets, with PD-1 and PD-L1 inhibitors being dominant. There are 220 clinical trials for HCC treatment, with the US leading. Biologics targeting PD-1 and PD-L1 have gained traction. The introduction of five new agents is expected to drive market growth. Therapeutic agents targeting PD-1 and PD-L1 have shown effectiveness in HCC, and innovation and technological advancements are expected to improve outcomes.
The report covers market size and growth, segmentation, competitive landscape, trends and strategies for global hepatocellular carcinoma treatment market. It presents a quantitative analysis of the market to enable stakeholders to capitalize on the prevailing market opportunities. The report also identifies top segments for opportunities and strategies based on market trends and leading competitors’ approaches.
The market is segmented based on various factors, including drug class, gender type, age group, and geography.
Drug class: chemotherapy, targeted therapy
Gender: men, women
Age group: below 29 years, 30-49 years, 50+ years
Segmentation by Geography
North America – US
Europe – Germany, France, UK, Italy, Spain
APAC – China, Japan
Chemotherapeutic drugs will remain dominant in the global HCC therapeutics market, but targeted therapies are expected to grow rapidly. The approval of biologics like Tecentriq (Atezolizumab) will drive the HCC treatment market. Research into novel mechanisms of action (MOAs) aims to address treatment non-response. The launch of new drugs targeting moderate-to-severe patients will drive market growth. Biologics targeting PD-1 and PD-L1 are gaining popularity.
Men will have a significant share in the HCC treatment market due to higher prevalence. The 50 years and above age group dominates the market.
The United States is the leading market due to affordability, awareness, and technology. China will experience fast growth due to improved healthcare access and expenditure. The US holds a significant market share of 48.3% in the HCC treatment market among the eight major markets.
The global HCC treatment market has numerous companies offering generic and patented drugs. The FDA approved Nivolumab, Keytruda, and Tecentriq for HCC treatment. Biologics and targeted therapies are changing the treatment landscape. Key players include Abbisko Therapeutics Co., Ltd., Advenchen Laboratories, LLC., Akeso, Inc., AstraZeneca plc, Bayer AG, BeiGene, Ltd., Bristol-Myers Squibb Company, Eli Lilly and Company, Exelixis, Inc., F. Hoffmann-La Roche AG, Genoscience Pharma SAS, Innovent Biologics, Inc., Jiangsu Hengrui Pharmaceuticals Co., Ltd., Merck & Co., Inc., Novra Technologies Inc., Pfizer Inc., Sanofi S.A., Shanghai Henlius Biotech Inc., Surface Oncology, Inc., Suzhou Zelgen Biopharmaceuticals Co., Ltd., TaiRx, Inc., Virogin Biotech Ltd., and Yiviva Inc. These companies invest in research, collaborations, acquisitions, and innovation to compete in the market.
Recent Industry Developments
Roche announced in May 2020 that the Food and Drug Administration approved the use of atezolizumab in combination with bevacizumab (Tecentriq) for the treatment of unresectable or metastatic hepatocellular carcinoma in patients without prior systemic therapy. This approval was based on findings from the international IMbrave150 (NCT03434379) trial, which involved patients with locally advanced unresectable or metastatic hepatocellular carcinoma who had not received prior systemic therapy.
In May 2019, Eli Lilly and Company announced that the Food and Drug Administration approved ramucirumab (Cyramza) as a standalone treatment for hepatocellular carcinoma (HCC) in patients with an alpha-fetoprotein (AFP) level of ≥ 400 ng/mL who had previously been treated with sorafenib. This approval was based on data from the REACH-2 (NCT02435433) study, a double-blind, placebo-controlled, multinational trial conducted in 292 patients with advanced HCC and AFP levels ≥ 400 ng/mL who had experienced disease progression on or after sorafenib treatment or were intolerant to it.
Scope of the Report
To analyze and forecast the market size of the global hepatocellular carcinoma treatment market.
To classify and forecast the global hepatocellular carcinoma treatment market based on drug class, gender, age group, geography.
To identify drivers and challenges for the global hepatocellular carcinoma treatment market.
To examine competitive developments such as mergers & acquisitions, agreements, collaborations and partnerships, etc., in the global hepatocellular carcinoma treatment market.
To identify and analyze the profile of leading players operating in the global hepatocellular carcinoma treatment market.
Why Choose This Report
Gain a reliable outlook of the global hepatocellular carcinoma treatment market forecasts from 2023 to 2029 across scenarios.
Identify growth segments for investment.
Stay ahead of competitors through company profiles and market data.
The market estimate for ease of analysis across scenarios in Excel format.
Strategy consulting and research support for three months.
Print authentication provided for the single-user license.
Global Hepatocellular Carcinoma Treatment Market 2023 - Report Scope
|Market Size (2022)
USD 3.22 Billion
Drug Class, Gender, Age Group, Geography
Abbisko Therapeutics Co. Ltd., Advenchen Laboratories LLC., Akeso Inc., AstraZeneca plc, Bayer AG, BeiGene Ltd., Bristol-Myers Squibb Company, Eli Lilly and Company, Exelixis Inc., F. Hoffmann-La Roche AG, Genoscience Pharma SAS, Innovent Biologics Inc., Jiangsu Hengrui Pharmaceuticals Co. Ltd., Merck & Co. Inc., Novra Technologies Inc., Pfizer Inc., Sanofi S.A., Shanghai Henlius Biotech Inc., Surface Oncology Inc., Suzhou Zelgen Biopharmaceuticals Co. Ltd., TaiRx Inc., Virogin Biotech Ltd., Yiviva Inc.